The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
By cutting pain crises & boosting haemoglobin
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The results were consistent across both the 10 mg and 40 mg treatment arms
The trial also demonstrated significant improvements across multiple secondary endpoints
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
